EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access · CC BY 4.0

Phase Ia study to evaluate RO7497987, a FLT3L-fragment Fc fusion protein, in healthy volunteers

Anthony J Iacovelli, Shomyseh Sanjabi, Sharareh Monemi, Assaf Amitai, Jérémie Decalf, Christine Moussion, Michael Z Liao, Gautham K Rao, Jennifer Getz, Michael R Mancuso

Frontiers in Immunology · 24.03.2026 · 17

DOI: 10.3389/fimmu.2026.1784546 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Frontiers in Immunology, online erschienen am 24.03.2026. Verfasst von Anthony J Iacovelli und 9 weiteren Autor:innen. Beteiligte Einrichtung: Genentech, Inc., South San Francisco, CA, United States. Hauptthemen laut MEDLINE: Immunoglobulin Fc Fragments, Membrane Proteins, Recombinant Fusion Proteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Genentech.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Dendritic cells play a critical role in immunity. Fms-related tyrosine kinase 3 ligand (FLT3L) is a cytokine that can promote the expansion and differentiation of bone marrow dendritic cells (DC) progenitors. RO7497987 (FLT3L-Fc) is a novel FLT3 agonist developed to extend the half-life of FLT3L and induce expansion of peripheral blood DC.

Methods

This Phase Ia trial evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of RO7497987 in healthy volunteers. Forty-four participants received RO7497987 as a single ascending dose (SAD, 0.7–70 mg) or multiple ascending doses (MAD, 7 or 21 mg, 21 days apart).

Results

RO7497987 was safe and well-tolerated at all doses. The most common treatment-related adverse events (AE) were Grade 1 myalgia, headache, and lymphadenopathy, all of which resolved spontaneously. There were no Grade ≥ 3 AEs, serious AEs, or dose-limiting adverse events. Pharmacokinetic analysis showed dose-dependent increases in FLT3L-Fc C max and AUC inf with no accumulation in the MAD cohorts. RO7497987 administration resulted in dose-dependent expansion of monocytes, as well as expansion of all major DC subsets, including conventional and plasmacytoid DC, which was sustained with multiple doses.

Conclusion

These findings aid the design of dosing regimens of RO7497987 as an immunomodulatory agent. Clinical trial registration https://www.isrctn.com/ISRCTN92655801 , identifier ISRCTN92655801.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunoglobulin Fc FragmentsMembrane ProteinsRecombinant Fusion ProteinsAdultFemaleHumansMaleMiddle AgedYoung AdultDendritic CellsHealthy Volunteers

Stichwörter der Autor:innen

FLT3L-FcFms-related tyrosine kinase 3 ligandRO7497987clinical trialdendritic cells

Substanzen

flt3 ligand proteinImmunoglobulin Fc FragmentsMembrane ProteinsRecombinant Fusion Proteins

Autor:innen und Institutionen

  • Genentech, Inc., South San Francisco, CA, United States.

Förderung

  • Genentech

Zitieren

APA

Iacovelli, A. J., Sanjabi, S., Monemi, S., Amitai, A., Decalf, J., Moussion, C., Liao, M. Z., Rao, G. K., Getz, J., & Mancuso, M. R. (2026). Phase Ia study to evaluate RO7497987, a FLT3L-fragment Fc fusion protein, in healthy volunteers. Frontiers in Immunology, 17. https://doi.org/10.3389/fimmu.2026.1784546

Vancouver

Iacovelli AJ, Sanjabi S, Monemi S, Amitai A, Decalf J, Moussion C, et al. Phase Ia study to evaluate RO7497987, a FLT3L-fragment Fc fusion protein, in healthy volunteers. Frontiers in Immunology. 2026;17. doi:10.3389/fimmu.2026.1784546

BibTeX
@article{Iacovelli2026,
  author = {Iacovelli, Anthony J and Sanjabi, Shomyseh and Monemi, Sharareh and Amitai, Assaf and Decalf, Jérémie and Moussion, Christine and Liao, Michael Z and Rao, Gautham K and Getz, Jennifer and Mancuso, Michael R},
  title = {Phase Ia study to evaluate RO7497987, a FLT3L-fragment Fc fusion protein, in healthy volunteers},
  journal = {Frontiers in Immunology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fimmu.2026.1784546}
}
Kostenlos starten →